SCHEMBL15937211

SCHEMBL15937211

CCOC(=O)/C(N)=C(\C)NCc1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 4/20 0.46
NPC1 O15118 3/20 0.45
PPID Q08752 2/20 0.45
PPIB P23284 1/20 0.45
PPIA P62937 1/20 0.45
PPIG Q13427 1/20 0.45
HPGD P15428 3/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 2/20 0.42
DHODH Q02127 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15937096 0.87 KMT2A (0.51) SMN1; SMN2NPC1HPGDALDH1A1KDM4E
SCHEMBL17359190 0.82 SMN1; SMN2 (0.46) SMN1; SMN2LMNANPC1PPIDPPIB
SCHEMBL15937210 0.81 SMN1; SMN2 (0.56) SMN1; SMN2LMNANPC1HPGDALDH1A1
SCHEMBL15937212 0.80 SMN1; SMN2 (0.50) SMN1; SMN2LMNANPC1HPGDALDH1A1
SCHEMBL12143938 0.80 SMN1; SMN2 (0.57) SMN1; SMN2LMNANPC1HPGDALDH1A1
SCHEMBL9136581 0.76 LMNA (0.69) SMN1; SMN2LMNANPC1HPGDKDM4E
SCHEMBL28050187 0.76 SMN1; SMN2 (0.50) SMN1; SMN2LMNANPC1HPGDALDH1A1
SCHEMBL26202136 0.73 SMN1; SMN2 (0.43) SMN1; SMN2LMNANPC1PPIDPPIB
SCHEMBL5528831 0.73 CYP2C9 (0.66) SMN1; SMN2LMNANPC1HPGDALDH1A1
SCHEMBL215283 0.73 PPID (0.56) SMN1; SMN2LMNAPPIDALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180127430-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2018-05-10 US disclosed
US-20180127430-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2018-05-10 US disclosed
US-9708335-B2 Spiro-lactam NMDA receptor modulators and uses thereof Apytinyx Inc. (US) 2017-07-18 US disclosed
US-9708335-B2 Spiro-lactam NMDA receptor modulators and uses thereof Apytinyx Inc. (US) 2017-07-18 US disclosed
EP-2951185-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2016-12-21 EP disclosed
US-20150368254-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2015-12-24 US disclosed
US-20150368254-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2015-12-24 US disclosed
WO-2014120800-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF NAUREX, INC. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127430-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A SMN1; SMN2 913/4885LMNA 4431/4885NPC1 1322/4885
US-20150368254-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A SMN1; SMN2 913/4885LMNA 4431/4885NPC1 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.